Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study
Abstract
In a placebo-controlled study, propafenone efficacy and safety for pharmaceutical cardioversion in atrial fibrillation (AF) paroxysms were studied. The study included 50 patients aged 28-69 years (mean age 53,9+9,7), with AF paroxysms lasting for less than 48 hours. Participants were randomized to propafenone (single dose of 600 mg, per os) or placebo. Eight hours later, sinus rhythm was restored in propafenone group more effectively than in placebo group: 85,7% and 33,3%, respectively (p=0,001). Mean sinus rhythm restoring time was 2,5+1,9 and 3,8+1,5 hours, respectively.
About the Authors
Yu. A. Bunin
Российская медицинская академия последипломного образования
Russian Federation
Russian Federation
L. K. Anfalova
Российская медицинская академия последипломного образования
Russian Federation
Russian Federation
References
1. Бунин Ю.А. Лечение тахиаритмии сердца. Москва, 2003. -С. 15-20.
2. Хамицаева Е.О., Шевченко Н.М., Богданова Е.Я., и др. Сравнительная эффективность однократного приема внутрь амиодарона и пропафенона в купировании пароксизмального мерцания предсердий//Российский кардиологический журнал. 2003;2:49-52.
3. ACC/AHA/ESC guidelines for management of patients with atrial fibrillation//Circulation 2001;104:2118-2150.
4. Azpitarte J., Alvarez M., Baun O., et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation//Eur. Heart J. 1997; 18:1649-1654.
5. Benjamin E.J., Wolf P.A., D' Agostino R.B., et al. Impact of atrial fibrillation on risk of death. The Framingham Heart Study//Circulation. 1998; 98:946-952.
6. Boriani G., Capucci A., Lenzi T. et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration//Chest. 1995;108:355-358.
7. Capucci A., Boriani G., Botto G.L., et al. Conversion of recentonset atrial fibrillation by a single oral loading dose of propafenone or flecainide//Am. J. Cardiol. 1994;74:503-505.
8. Connolly S.J., Kates R.E., Lebsack C.S. et al. Clinical pharmacology of propafenone//Circulation. 1983; 68:589-596.
9. Dukes I.D., Vaughan Williams E.M. The multiple modes of action of propafenone//Eur. Heart J. 1984;5:115-125. 17.
10. Flegel K.M., Shipley M.J., Rose G. Risk of stroke in non-rheumatic atrial fibrillation//Lancet. 1987;1:526-529.
11. Johan E.P., Wakfare. Acute treatment of atrial fibrillation. Why and when to maintain sinus rhythm//Am. J. Cardiol. 1998, march 19.
12. Kastor J.A. Arrhythmias. Philadelfia: W.B Saunders company. 1994, p. 25-124.
13. Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation//J. Am. Coll. Cardiol. 2001;37:542-547.
14. Khan I.A Atrial stunning: determinants and cellular mechanisms//Am. Heart J. 2003;145: 787-794.
15. Kingma J.H., Suttorp M.J. Acute pharmacologic conversion of artial fibrillation and flutter: the role of flecainide, propafenone and verapamil//Am. J. Cardiol. 1992;70: 56A-60A
16. Miller J.M., Zipes D.P. Management of the patient with cardiac arrhythmias/In Braunwald E., Zipes D., Libby P. (eds). Heart disease. A text-book of cardiovascular medicine. Philadelphia: W.B. Saunders company. 2001. P. 728.
17. Reimold S., Maisel W., Antman F. Propafenone for the treatment of supraventricular tahicardia and atrial fibrillation: a meta-analysis//Am. J.Cardiol. 1998;82: 66-71.
18. Van Gelder I.С, Tuinenburg A.E., Schoonderwoerd B.S. et al. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation//Am. J. Cardiol. 1999;84:147R-151R.
19. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study//Stroke. 1991;22: 983-988.
Review
For citations:
Bunin Yu.A., Anfalova L.K. Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study. Russian Journal of Cardiology. 2005;(6):57-61. (In Russ.)
Views:
452
Email this article 